Hypersensitivity Reaction and Hepatotoxicity in Patients Receiving Integrase Inhibitors
Latest Information Update: 07 Sep 2023
Price :
$35 *
At a glance
- Drugs Abacavir (Primary) ; Dolutegravir (Primary) ; Elvitegravir (Primary) ; Raltegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms EuroSIDA
- 08 Oct 2020 Results presented at the 15th International Congress on Drug Therapy and HIV Infection
- 07 Dec 2017 New trial record
- 27 Oct 2017 Results (n=1217) presented at the 16th European AIDS Conference